Zymeworks Debt to Equity Ratio 2016-2022 | ZYME

Current and historical debt to equity ratio values for Zymeworks (ZYME) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Zymeworks debt/equity for the three months ending March 31, 2022 was 0.00.
Zymeworks Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.15B $0.28B 0.52
2021-12-31 $0.14B $0.25B 0.56
2021-09-30 $0.14B $0.28B 0.51
2021-06-30 $0.15B $0.32B 0.47
2021-03-31 $0.11B $0.38B 0.30
2020-12-31 $0.13B $0.41B 0.31
2020-09-30 $0.14B $0.43B 0.32
2020-06-30 $0.12B $0.49B 0.24
2020-03-31 $0.11B $0.52B 0.22
2019-12-31 $0.12B $0.25B 0.50
2019-09-30 $0.09B $0.31B 0.29
2019-06-30 $0.08B $0.33B 0.24
2019-03-31 $0.07B $0.17B 0.40
2018-12-31 $0.06B $0.18B 0.36
2018-09-30 $0.03B $0.17B 0.15
2018-06-30 $0.03B $0.19B 0.13
2018-03-31 $0.02B $0.10B 0.20
2017-12-31 $0.02B $0.12B 0.13
2017-09-30 $0.02B $0.08B 0.21
2017-06-30 $0.02B $0.10B 0.18
2017-03-31 $0.03B $0.05B 0.61
2016-12-31 $0.03B $0.07B 0.39
2016-09-30 $0.00B $0.00B 0.00
2016-06-30 $0.00B $0.00B 0.00
2016-03-31 $0.00B $0.00B 0.00
2015-12-31 $0.01B $0.02B 0.27
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.320B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00